

COST ACTION CA 17140

NANO2CLINIC

CANCER NANOMEDICINE - FROM THE
BENCH TO THE BEDSIDE



COST Action CA1710

4th MC Meeting
online - 31/01/2022



Funded by
the European Union

Welcome to participants - MC members

AL	Prof. Albana Ndreu Halili	IE	Dr. Oliviero Gobbo and Dr. Nanasheeb Thorat
AT	Dr. Andreas Falk and Prof. Ruth Prassl	IL	Prof. Nissim Garti and Dr. Sharon Garti-Levi
BA	Prof. Verica Pavlic and Prof. Sinisa Ristic	IT	Prof. Maria F. Ottaviani and Prof. Sabrina Pricl
BE	Prof. Stefaan de Smedt	LU	Dr. David Duday
BG	Prof. Ivo Grabchev and Prof. Ivaylo Dimitrov	LV	Dr. Maria Issagouliantis and Dr. Arturs Abols
CH	Prof. Carlo Catapano and Dr. Oleksii Morozov	MK	Prof. Aleksandar Dimitrov and Dr. Beti Andonovik
CY	Prof. Christakis Damianou and Dr. Triantafyllos Stylianopoulos	NL	Prof. Hong Zhang and Dr. Sylvestre Bonnet
CZ	Prof. Pavla Bojarova and Dr. Dominika Wrobel	NO	Prof. Kirsten Sandvig and Dr. Yrr Mørch
DE	Dr. Nazende Günday Türeli and Dr. Dietmar Appelhans	PL	Prof. Joanna Wietrzyk and Prof. Barbara Klajnert-Maculewicz
DK	Prof. Jørn B. Christensen	PT	Dr. Helena Tomás and Dr. Carla Cruz
EE	Dr. Olesja Bondarenko and Prof. Tambet Teesalu	RO	Dr. Sanda Boca-Farcau and Dr. Marin Gheorghe
EL	Dr. Cecile Arbez-Gindre and Dr. Eleni Efthimiadou	RS	Prof. Biljana Potparevic and Dr. Romana Masnikosa
ES	Dr. Maria A. Muñoz Fernández and Prof. Valentín Cena	SE	Prof. Susana Cristobal and Prof. Michael Malkoch
FI	Prof. Heikki Tenhu and Prof. Hélder Santos	SI	Dr. Marija Vukomanovic and Dr. Nina Kostevšek
FR	Dr. Ling Peng and Dr. Maria Eugenia Riveiro	SK	Dr. Monika Sramkova and Dr. Katarína Kozics
HR	Prof. Mariastefania Antica and Dr. Ivana Vinković Vrček	TR	Prof. Rana Sanyal and Mr. Sena Nomak
HU	Prof. Janos Szebeni and Dr. Tamas Letoha	UK	Prof. David K. Smith and Dr. Alan Hunter

Welcome to participants – SO and CG members

Science Officer

Dr. Lucia Forzi (EC)

WG vice-leaders:

- Dr. Tomas Strasak (WG1, CZ)
- Dr. Evgeny Apartsin (WG2, RU)
- Prof. Ulf D. Kahlert (WG3, DE)
- Dr. Enrico Catalano (WG4, IT)

GH Manager

- Mrs. Joanna Korczynska (PL)

Verification of the quorum

- 34 COST Countries represented on the CA17140 MC
- $2/3 = 23$ **COST Countries** must be present at this meeting
- Verification of online attendees resulted in quorum condition:
 - **Satisfied**
 - Unsatisfied

Adoption of the Agenda

- The MC committee result is:
 - **Adopted**
 - Not adopted

Approval of 3rd MC meeting minutes and matters arising from last meeting

- Minutes of the 3rd MC meeting are available at:
<https://www.nano2clinic.eu/3rd-ca17140-mc-meeting-online-october-2020>
- The MC committee result is:
 - **Approved**
 - Not approved
- No matters arising from last meeting to discuss

Update from the CA17140 Science Officer

Dr. Lucia Forzi (EC)

Update from the CA17140 Chair

Update from the Action Chair

Status of the Action

Action Details

MoU - 060/18

CSO Approval date - 13/04/2018

Start date - 28/09/2018

End date - 27/09/2022


- Number of represented COST Countries*: **34**
- Number of represented COST ITC countries*: **18**
- Number of MC members*: **64**

COST Members

The **38** COST Members are: Albania, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, **Iceland**, Ireland, Italy, Latvia, Lithuania, Luxembourg, **Malta**, **the Republic of Moldova**, **Montenegro**, The Netherlands, The Republic of North Macedonia, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, United Kingdom

Cooperating Member

Israel is a Cooperating Member



Update from the Action Chair

- **New COST rules enforced by November 1st 2021 – Horizon Europe**
 - **COST ITC Countries**

OLD RULE

- Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, North Macedonia, Hungary, Latvia, Lithuania, **Luxembourg**, Malta, Moldova, Montenegro, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Turkey.

NEW RULE

- Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, **Greece**, North Macedonia, Hungary, Latvia, Lithuania, Malta, Moldova, Montenegro, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Turkey


Update from the Action Chair

- **New COST rules enforced by November 1st 2021 – Horizon Europe**

- **COST NNC Countries**

Algeria, Armenia, Azerbaijan, Belarus, Egypt, Georgia, Jordan, Kosovo, Lebanon, Libya, Morocco, the Palestinian Authority, Russia, Syria, Tunisia and Ukraine

The designation of Kosovo is without prejudice to position on status, and is in line with UNSCR 1244/1999 and the ICJ Opinion on the Kosovo declaration of independence



Update from the Action Chair

New CA17140 Leadership (Core Group)

Action Chair: Prof Sabrina Pricl (IT)

Action Vice-Chair: Dr Nazende Günday Türeli (DE)

Grant Holder (GH) Scientific Representative: Prof Barbara Klajnert-Maculewicz (PL, ITC)

Science Communication Coordinator: Dr. Maria Eugenia Riveiro (FR)

WG1 Leader: Prof Rana Sanyal (TR, ITC)

WG1 Vice-leader: Dr. Tomas Strasak (Young researcher/innovator, CZ, ITC)

WG2 Leader: Dr Ivana Vinković Vrček

WG2 Vice-leader: Dr. Evgeny Apartsin (Young researcher/innovator, RU, NNC)

WG3 Leader: Prof Carlo Catapano (CH)

WG3 Vice-leader: Prof. Ulf Kahlert (Young researcher/innovator, DE)

WG4 Leader: Dr Maria Eugenia Riveiro (FR)

WG4 Vice-leader: Dr. Enrico Catalano (Young researcher/innovator, IT)

Grant Awarding Coordinator: Prof. Maria Francesca Ottaviani (IT)

GH Manager: Mrs. Joanna Korczynska (PL, ITC)

Update from the Action Chair

There is a vacant position as MC member for Italy

- Interested candidates should contact the Italian CNC
 - Dr Valentina Cardinale +390697727549
 - valentina.cardinale@miur.it
 - Ministry of Education, University and Research Department of Higher Education and research – DG Research; Office VIII – Programming and promotion of research in the international context and coordination of aerospace research Via Carcani 61 00153 Rome Italy

Update from the Grant Awarding Coordinator: review of completed reports and new applications

Grant Awarding Coordinator – Prof. Maria Francesca Ottaviani

Update from the Grant Holder: Action Budget Status

GH Manager – Mrs. Joanna Korczynska (PL)

Request of MC voting for appointing Dr. Maria Eugenia Riveiro as Science Communication Coordinator

MC voting to appoint new CA17140 SCC

- Former SCC: Prof. Sabrina Prici
 - The role has been terminated due to new leadership position
- Upon request by the CG, Dr. Maria Eugenia Riveiro (SME, FR, CG member) has kindly accepted to serve as SCC
- MC voting is required for this appointment
- Results of the voting:
 - **Approved**
 - Rejected

Update from the Science Communication Coordinator





Dr. Maria Eugenia Riveiro (FR)

Implementation of COST policies

Inclusiveness and excellence


- The COST inclusiveness policy is developed around **three main elements**:
 - Gender balance
 - Career stage: involving young researchers
 - Geographical spread
- The COST excellence policy is also developed around **three main elements**:
 - Identifying excellence in science and technology across Europe
 - increasing research communities' access to funding and infrastructures
 - triggering structural changes in Members' national research systems

Promotion of gender balance





MC Online Meeting

Promotion of Young Researchers/Innovators




Leadership role will drastically increase with the proposed corrective actions (discussed later)





MC Online Meeting



Inclusiveness and excellence – ITCs



Leadership role will further increase with the proposed corrective actions (discussed later)



MC Online Meeting

Participation from all countries
Remarkable participation from Australia, China and India

Excellence



This slide
intentionally left
blank

Excellence



- **33%** of MC members have responded to the issued questionnaire
- **24%** of Action members have responded to the issued questionnaire
- The questionnaire is an indispensable tool for:
 - Checking the Action activity in response to COST three main elements
 - Preparing the Action final report
- Another round of Action questionnaire will be issued close to Action deadline
 - A more effective collaboration from all Action members is mandatory

Follow-up of MoU objectives: progress report from working groups

Update from WG1 - WG1 Leader – Prof. Rana Sanyal (TR) WG1 Vice-leader – Dr. Tomas Strasak (CZ)

Update from WG2 - WG2 Leader – Dr. Ivana Vinković Vrček (HR) WG2 Vice-leader – Dr. Evgeny Apartsin (RU)

Update from WG3 – WG3 Leader – Dr. Carlo Catapano (CH) WG3 Vice-leader – Prof. Ulf Kahlert (DE)

Update from WG4 – WG4 Leader – Dr Maria Eugenia Riveiro (FR) WG4 Vice-leader – Dr. Enrico Catalano (IT)

Scientific planning

Scientific Strategy - MoU

Action Primary Objective (Challenge):

To develop nanosystems carrying anticancer drugs from their initial design, pre-clinical testing of efficacy, pharmacokinetics and toxicity to the preparation of protocols needed for the first phase of their clinical use

Scientific Strategy –Secondary objectives

1. Promoting and fostering active and multidisciplinary collaborations between industry and academia on each aspect of the design, development, and translation of cancer nanomedical agents ✓
2. Fostering synergies between complementary EU groups of excellence, thereby expanding the network beyond existing collaborations between Action partners, with particular attention to the strong, active involvement of SMEs, regulatory agencies, academic clinical research centers, clinical research organizations, and other public/industrial entities ✓
3. Promoting cross-pollination of competencies and transferring results within the EU actors belonging to public and private sectors by extensive exchange of PhD students, young researchers and senior scientists, meetings and workshops, and collaborative scientific publications and patents ✓
4. Disseminating results to all potential stakeholders, including public organisms, funding agencies, patients associations and the general public to increase EU citizen awareness of the social benefits of the Action results ✓
5. Creating strong partnership between academia and industry by the equal participation of these two groups ✓
6. Training and mentoring of young generations of researchers working in academia and industry to pave their way towards autonomous research leadership ✓
7. Ensuring equal opportunities by providing equal access to COST activities, respecting balanced gender distribution ✓
8. Involving participants from less research active countries according to the inclusiveness policy of COST ✓

4th GP goals

- GAPG 1: to define a set of standard *in vitro* testing methods of nanomaterials
- GAPG 2: to define a set of standard *in vivo* testing methods of nanomaterials
- GAPG 3: to determine the key factors imparting *in vitro* proof of concepts in oncology
- GAPG 4: to prepare guidelines for translation of nanomedicines from bench to market
- GAPG 5: to prepare guidelines concerning regulatory aspects of nanomedicines
- GAPG 6: to disseminate Action's non-confidential results to public and to further develop a platform for on-line networking activity
- GAPG 7 to monitor Action progress, formulate corrective guidelines, and foster networking activity
- GAPG 8 to foster young scientists and innovators' involvement in the Action Challenge

4th GP Deliverables – WG3

- D3.1. Consensus protocols for *in vitro* testing of nanomaterials (**M36**)
- D3.2. Consensus protocols for *in vivo* testing of nanomaterials (efficacy, toxicology and pharmacokinetic studies) (**M36**)
 - MS3.1. Complete determination of key factors/mechanisms imparting *in vitro* proof of concept in oncology and cellular uptake/trafficking of selected nanomedicines (Y/N)
 - MS3.2. Complete determination of *in vivo* efficacy, ADME and the toxicity profile characterization of selected nanomedicines in preclinically relevant animal models (Y/N)
- Deployment delayed → WG3 meeting will elaborate these CA17140 fundamental deliverables and MS achievement → expected deployment date June 2022

WG3 Meeting

Relation to GP goals: GAPG1, GAPG2, GAPG3, GAPG4 and GAPG8

Location: **Bellinzona (CH)**

Organizer: **Dr. Carlo Catapano (WG3 leader)**

Date: from **2022-03-03** 9 am to **2022-03-04** 6 pm (2 days)

Number of expected total participants:

10 people/day – presence sheet signature required (5 to be reimbursed by COST for 2 day)

Aims and scope:

summarizing the state-of-the-art and preparing the final Action deliverables concerning the guidelines and roadmaps for *in vitro/in vivo* successful testing and translation of cancer nanomedicines

Output(s)

Preparation and drafting of the WG3 expected deliverables/related milestones fulfillment and position papers

WG3 Workshop (WS)

Relation to GP goals: GAPG1, GAPG2, GAPG3, GAPG4, GAPG5, GAPG6 and GAPG8

WS title: **Advancing cancer nanomedicine to the clinics: hypes, hopes and hurdles**

Location: **Magdeburg (DE)**

Organizer: **Prof. Ulf D. Kahlert (WG3 Vice-leader, Young/Innovator member)**

Date: from **2022-06-16** 9 am to **2022-06-17** 6 pm (2 days)

Number of expected total participants:

15 people/day – presence sheet signature required (5 to be reimbursed by COST)

WG3 Workshop (WS)

Aims and scope:

- Generation of a think-tank for defining the state of the art assays for cancer modeling to support clinical meaningful preclinical nano-drug/nano-theranostic development
- Promoting the commitment and pro-actively engaging clinicians (in particular surgeons and radiologists) in the activity of the Action both within the granting period and beyond - to foster clinical application of new nano-drugs against cancer
- Present and discuss perspective clinical trials with new nano-drugs, especially for agents based on pure synthetic background – identifying “needs” from the clinician standpoints
 - Also, there will be presentations concerning an emerging field, the **combination of nanomedicine and artificial intelligence (AI) in cancer clinical and surgical management**, with the further aim of identifying complementing synergies of these frontier fields of research

WG3 Workshop (WS)

Outputs:

1. To stir more interest and involvement and inform the clinical/surgeon community about the success of nanomedicine in cancer therapy and rise awareness about the hurdles that still need to be overcome for successful clinical translation of cancer nanomedicines
2. To provide material to WG3 and WG4 to finalize the relevant deliverables
3. To deploy one or possibly two consensus papers in peer-reviewed (possibly OA) journal articles in the context of the above mentioned topics
4. To create a critical mass for defining projects and agenda for future joint grant applications associated to cancer nano-medicine (at national, bi-national, and multi-national EU levels)

4th GP Deliverables – WG4

- D4.1. Formulation of guidelines and documents for translation of nanomedicines from bench to bed/market (**M48**)
- D4.2. Formulation of guidelines and documents concerning regulatory aspects of nanomedicines (**M48**)
 - MS4.1. Documents for translation of selected nanomedicines (Y/N)
 - MS4.2. Documents for suggested regulatory aspects of selected nanomedicines(Y/N)
- WG4 meeting will elaborate these CA17140 fundamental deliverables and MS achievement → expected deployment: on time

WG4 Meeting

Relation to GP goals: GAPG4, GAPG5, GAPG6 and GAPG8

Location: **Istanbul (TR, ITC)**

Organizers: **Dr. Maria Eugenia Riveiro (WG4 leader) and Dr. Rana Sanyal (WG1 leader)**

Date: from **2022-06-7** 9 am to **2022-06-8** 6 pm (2 days)

Number of expected total participants:

15 people/day – presence sheet signature required (7 to be reimbursed by COST)

Aims and scope:

- Preparing the final Action deliverables concerning what is perhaps the **most critical aspect of the Action**: the guidelines and roadmaps concerning successful translation and regulatory aspects of cancer nanomedicines
- Special focus: specific issue of cancer nanomedicine toxicity, with explicit reference to the actual challenges in the development of new standardized methods required for cancer nanomedicine clinical translation as well as regulation issues that are still lacking for their marketing authorization
- Organizers belong to SME

Action Budget Planning

Action budget planning (APB)

- AGA-CA17140-4 (GP4) is the last grant period
- WBP4 has been finally signed on January 24, 2022
- WBP4 is now operative and will last till the end of the Action (**2022-09-27**)
- Accordingly, no Action budget planning is required
- However, should we submit a request for Action extension we will have to prepare an ABP (for initiatives and eventual underspending carryover) (discussed later)

Long term Planning

Long term planning

Events already scheduled for WBP4 with budget

- STSM & ITC grants (discussed)
- WG3 meeting (discussed)
- WG3 workshop (discussed)
- WG4 meeting (discussed)
- STSM Conference 1 and 2
- 5th MC Meeting
- CA17140 Final Conference
- 2nd Training School

Events already scheduled or to be organized in WBP4 with no budget

- “Science and the Action” bi-weekly series of webinars from MC and any Action member
- WG Info days: Four 1-hour online meetings with all members (grouped by WG)
- Online webinars for mentoring academic and industrial career of Young researchers/Innovators (on demand)
- Online webinars involving major European Entities and Governing bodies in the Action field (e.g., EMA, ...)

Long term planning: STMS Conference 1 and 2

Relation to GP goals: GAPG6 and GAPG8

Conference title: **1st STSM Conference and 2nd STSM Conference**

Location: **online**

Dates: 1st STSM Conference **2022-03-16** from 9 am to **2022-03-16** 6 pm (1 day)

2nd STSM Conference **2022-09-22** from 9 am to **2022-09-22** 6 pm (1 day)

Main organizer: **Prof. Maria Francesca Ottaviani** (Grant Awarding Coordinator)

Organizing and Scientific Committee: **composed by Young Researchers/Innovators, appointed by Prof. Ottaviani in response to a call issued among this class of STSM grantees**

Aims and scope:

prominent role of disseminating to the widest possible public the results (both in terms of scientific production, networking, jointed proposals, etc.) originated through STSM grants

All grantees are requested to present their contribution to this event

In order to include also those grantees whose activity is still ongoing or is to be carried out during this WBP, the 2nd STSM Conference is scheduled in September 2022

Number of expected total participants: 50 per event

Outputs: Official Action book of abstracts

recorded presentations (upon granted permissions) edited and hosted on the action website and made publicly available

Long term planning: 5th MC meeting

Relation to GP goals: GAPG6 and GAPG7

Location: **online** (in order to ensure the full presence of all members in the framework of a still possibly ongoing pandemic situation)

Date: 2022-07-11 from 9 am to 2022-07-11 1 pm (1day)

Main organizers: **Action Chair and GH Manager**

Aims and scope:

- To update the MC about all major goals achieved by the Action by the end of the regularly foreseen activity
- In case of Action extension, to revise and discuss all activity eventually foreseen for the remaining period
- To summarize all statistics concerning all WGs and all WG goals
- To present and discuss the results of correction actions eventually enforced since the present MC meeting
- To present a global overview of the Action Budget distribution will be offered
- Each WG leader will briefly highlight the WG activity, goals and milestones
- The Grant Awarding Coordinator will report on the STSM results and achievements
- The chance of shaping a future COST Action will also be proposed and discussed

CA17140 Final Conference

Relation to GP goals: GAPG1, GAPG2, GAPG3, GAPG4, GAPG5, GAPG6 and GAPG8

Conference title: **CA17140 Final Conference**

Conference type: **hybrid** (in person and online, to ensure the maximum participation from all CA17140 members)

Location: **University of Trieste (home of the Action chair)** (the location has all facilities to provide a safe in-person environment and online conference broadcasting)

Organizer: **The Action Chair + Scientific and Organizing Committee** (TBD but **involving several Young/Innovator members**)

Date: from **2022-07-11** at 1 30 pm to **2022-07-12** 6 pm (2 days)

Number of expected total participants:

150 people/day – presence sheet signature /online access check required (16 to be reimbursed by COST)

Note: the choice of the CA17140 Final Conference date and modality is related to budget considerations

CA17140 Final Conference

Event description:

- Oral presentations will be preferred and a poster session will also be featured
- A further virtual poster session will also be featured
- The event aims at presenting major efforts/results gathered during the Action
- Young researchers/Innovators will be especially involved (in the Scientific and organizing Committee as well)
- Up to three keynote speakers will be invited to give milestone presentations about the major action topics
- Preliminary Conference agenda: the three keynote speakers will deliver the opening lecture the first day and the two opening lectures in the morning and afternoon of the second day, respectively
- Each keynote will be followed by oral presentations from different WG representatives
- Poster viewing will be available during the entire event

Outputs:

- Book of abstracts; recorded lectures (after written consent) will be hosted on the action website
- global conference overview on the website

CA17140 2nd Training School

Relation to GP goals: GAPG1, GAPG2, GAPG3, GAPG4 and GAPG8

Training school title: **Cancer Nanomedicine Training School**

Location: **Warsaw University of Life Sciences** (PL, ITC)

Local organizer: **Prof. Sławomir Jaworski**

Date: from **2022-09-01** at 9 am to **2022-09-03** at 6 pm (3 days)

Number of expected total participants:

10 trainers and 30 trainees (30 trainees to be reimbursed by COST)

CA17140 2nd Training School

Event description:


- The Second CA17140 Training School (TS) will bring together researchers from different disciplines with a unique and exciting format to learn the most current information about nanobiotechnology and nanomedicine advances
- It will be a perfect platform to share experience and foster collaborations

Aims and scope:

- This TS will address progress and prospects for nanomedicine, with special emphasis on *in vitro* and *in vivo* nanotoxicology and angiogenesis
- Some topics covered: glioblastoma, breast cancer and lung cancer
- Hands-on sessions on *in vitro/in ovo* assessment of nanoparticles against cancer, viability, morphology, and angiogenesis and *in vivo* toxicology
- This will be further complemented by practical information and advisory; comprehensive talks, special sessions, debates, and new perspective for future scientific cooperation

Outputs:

- increasing awareness of toxicity of nanosystems among Young Researchers/Innovators and senior researchers
- increasing knowledge about nanomedical applications in cancer treatment among Young Researchers/Innovators and senior researchers
- increasing laboratory expertise with special focus on *in vivo* techniques



“Science and the Action”

To foster and promote Action networking, knowledge exchange and general activity

Science and the Action: A **bi-weekly 1-hour** online series of seminars proffered by ACTION MC and/or any Action Member (young researchers and Innovators most welcome)

Location: **online** (no budget need, complying with COST recommendations under pandemic situation)

Date: **Every 1st and 3rd Friday from 3 to 4 pm**

Event description:

Each presentation (about 30 minutes, followed by Q&A) may consist in:

- Report of scientific activity/results, seminar on specific technique(s), laboratory presentation....

Organizers: Action Chair and Vice-Chair (Dr Nazende Günday Türeli) with an **Organizing Committee to be selected among Young Researchers/Innovators upon open call**

As MC members, you are strongly encouraged to send your contribution (title and preferred date) to N.Guenday-Tuereli@mybiotech.de (AND CC to cost_action_17140@icloud.com) starting TODAY!

The invitation to other Action members will be sent immediately after the MC meeting closure

WG info days

To foster and promote Action networking, to update the entire actions about MC meeting highlights and to receive further input

WG info days: A series of 4 online 1-hour meetings, one per WG

Location: **online** (no budget need, complying with COST recommendations under pandemic situation)

Date: **WG4 info day scheduled on February 8 and WG1 on February 9; other WG info day dates under finalization by the respective WG leaders**

Event description:

Each WG leader/vice-leader will organize the corresponding WG info day. The Chair/vice-Chair will also participate along with other CG volunteer members

Action participants will be grouped according to their WG affiliation and to a mechanism devised by the CG to avoid repetitions

WG info day slides will be made available on the website for those members who could not attend

WG info days will be repeated after the last MC meeting and any time the Action Chair will deem them necessary

Other online activities

Two further activities in the form of online webinars are foreseen:

- Online webinars dedicated to mentoring academic and industrial career of Young researchers/Innovators (on demand)
- Online webinars involving major European Entities and Governing bodies in the Action field (e.g., EMA, ...)

Proposals from the MC members (and from all Actions members) are highly recommended and most welcome

Please inform the Chair and vice-Chair about your ideas and proposals

Long term planning

Creating an Action critical mass to form Consortia within the Action to apply for international grants:

- Horizon Europe
- ERC Synergy grants
- ERC individual grants
- EuroNanoMed calls
- Other International and National agency calls...

According to the EC statistics, **proposal stemming from COST Actions have higher success rates!**

Action extension

There is the possibility to apply for an Action extension

- Based on the rules, extension can be **6 months maximum**
- **Extension request must be approved by MC** with e-voting (to be issued after this MC meeting)
- Extension must be submitted at least 6 months before action end date -> **March 26th is the last date for our Action**
- **No further budget is foreseen but eventual underspending can be carried over to the extension** (and the WBP must be prepared)
- A **detailed justification** for the extension must be described in the request → **no COVID-19 reasons accepted**
 - **All MC members and Action members must help in providing these justification on the basis of scientific, technical and networking reasons**

Dissemination planning

Dissemination planning/outreach activity

- Book from WG2 Conference (discussed)
- Book from the Action
 - The Chair will contact Elsevier and/or The Royal Chemical Society to establish the possibility to have a Book based on Action results
 - Chapters will span all 4 WGs and could be in the form of original work or review work (exclusively based on Action work)
- Thanks to our Action member, Prof. Bruno Sarmento, Elsevier has accepted to guest a special issue focused on our Action in European Journal of Pharmaceutical Sciences
 - All details are available on our website at:
<https://www.nano2clinic.eu/news/special-issue-european-journal-pharmaceutical-sciences-dedicated-our-action>

Dissemination planning/outreach activity

Must increase general public awareness and public engagement

- Preparation of **press releases/videos** with Action results, projects and interviews to be disseminated to different countries press and media agencies
 - Focus on major scientific/technological output, events, etc.
 - All MC must contribute to these (but will also involve all Action members during the WG info days)
 - The SCC will create a dedicated page on the website to host the press releases/videos
 - **The CG is already elaborating strategies for Action videos (thanks to Evgeny Apartsin) and there will be a call for MC members and Action members to volunteer**
 - **The contributions from Young Researchers/Innovators, from Industrial Members and from ITC Country Representatives are particularly important**
- The successful involvement of EC citizens will be one of the most added value of this Action

AOB

Location and date of the next meeting

5th MC Meeting

Location: **online** (in order to ensure the full presence of all members in the framework of a still possibly ongoing pandemic situation)

Date: **2022-07-11 from 9 am to 2022-07-11 1 pm (1day)**

Summary of MC decisions

Summary of MC decisions

- All WBP4 proposed activities were approved by the MC
- The results of MC voting to appoint Dr. Maria Eugenia Riveiro as the new Scientific Communication Coordinator is: **approved**
- The MC opinion to apply for a 6-month extension of the CA17140 activity is: **positive**
 - The required MC voting will be issued on e-COST by the Action Chair at the end of the MC meeting

Closing

“We should not be shy about being proud of where we are or ambitious about where we want to go.”

President Ursula von der Leyen